Published in Heart Vessels on November 27, 2006
Prospective randomized trial comparing a nitinol self-expanding coronary stent with low-pressure dilatation and a high-pressure balloon expandable bare metal stent. Heart Vessels (2008) 0.87
Network meta-analyses on in-stent restenosis treatment: dealing with complexity to clarify efficacy and safety. J Thorac Dis (2015) 0.78
Management of ischemic coronary disease in patients receiving chemotherapy: an uncharted clinical challenge. Future Cardiol (2017) 0.75
A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med (1994) 9.15
A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med (1994) 7.96
Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet (1998) 3.79
Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation (1999) 2.67
Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med (2001) 2.54
Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. N Engl J Med (2002) 2.52
Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation (2000) 2.28
Analysis of data from multiclinic trials. Control Clin Trials (1986) 2.01
Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation (1988) 1.74
Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet (2002) 1.72
Cutting balloon angioplasty for the treatment of in-stent restenosis: a matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty. J Am Coll Cardiol (2001) 1.48
Rotational atherectomy or balloon angioplasty in the treatment of intra-stent restenosis: BARASTER multicenter registry. Catheter Cardiovasc Interv (2000) 1.39
Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. Circulation (2000) 1.37
Strengths and limitations of meta-analysis: larger studies may be more reliable. Control Clin Trials (1997) 1.36
Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation (2002) 1.11
Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Am J Cardiol (1999) 0.97
Percutaneous transluminal angioplasty of saphenous vein graft stenosis: long-term follow-up. J Am Coll Cardiol (1989) 0.96
Directional coronary atherectomy for the treatment of Palmaz-Schatz in-stent restenosis. Am J Cardiol (1998) 0.91
Percutaneous transluminal coronary angioplasty in patients with prior coronary bypass surgery. J Am Coll Cardiol (1983) 0.88
Long-term angiographic and clinical outcome after implantation of balloon-expandable stents in aortocoronary saphenous vein grafts. Am J Cardiol (1994) 0.86
Directional atherectomy for treatment of restenosis within coronary stents: clinical, angiographic and histologic results. J Am Coll Cardiol (1992) 0.81
Treatment of in-stent restenosis with excimer laser coronary angioplasty: mechanisms and results compared with PTCA alone. Circulation (1997) 0.80
Comparison of intracoronary gamma radiation for in-stent restenosis in saphenous vein grafts versus native coronary arteries. Am J Cardiol (2003) 0.78
Laser angioplasty of restenosed coronary stents: results of a multicenter surveillance trial. The Laser Angioplasty of Restenosed Stents (LARS) Investigators. J Am Coll Cardiol (1999) 0.77
Review of intracoronary radiation for in-stent restenosis. J Invasive Cardiol (2003) 0.76
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med (2004) 12.58
Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol (2004) 2.97
Lack of association between migraine headache and patent foramen ovale: results of a case-control study. Circulation (2010) 2.88
Drug-eluting stents: an early systematic review to inform policy. Eur Heart J (2004) 2.88
The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol (2004) 2.78
A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol (2011) 2.78
A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol (2005) 2.56
Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation (2002) 2.53
Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation (2004) 2.35
The reporting of blinding in physical medicine and rehabilitation randomized controlled trials: a systematic review. J Rehabil Med (2013) 2.20
Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecol Oncol (2009) 2.16
Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA (2006) 2.16
A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol (2009) 2.14
Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial. J Am Coll Cardiol (2004) 2.05
Effect of endothelial shear stress on the progression of coronary artery disease, vascular remodeling, and in-stent restenosis in humans: in vivo 6-month follow-up study. Circulation (2003) 2.04
Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol (2012) 2.03
Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation (2004) 1.96
Medical device development: from prototype to regulatory approval. Circulation (2004) 1.90
Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation (2004) 1.83
VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol (2007) 1.79
Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation (2004) 1.72
Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation (2005) 1.67
Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol (2002) 1.62
Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation (2002) 1.61
Incidence and predictors of late total occlusion following coronary stenting. Catheter Cardiovasc Interv (2003) 1.61
Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. Circulation (2008) 1.59
A decade of improvement in the clinical outcomes of percutaneous coronary intervention for multivessel coronary artery disease. Circulation (2002) 1.58
Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol (2006) 1.56
Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol (2011) 1.56
Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. Circulation (2004) 1.54
Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial. J Am Coll Cardiol (2004) 1.53
Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol (2004) 1.52
Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol (2002) 1.51
Post-market approval surveillance: a call for a more integrated and comprehensive approach. Circulation (2004) 1.49
Cost-effectiveness of gamma radiation for treatment of in-stent restenosis: results from the Gamma-1 trial. Circulation (2002) 1.48
Angioplasty and stents in coronary artery disease: a systematic review and meta-analysis. Scand Cardiovasc J (2004) 1.47
Location of acute coronary artery thromboses in patients with and without chronic kidney disease. Kidney Int (2008) 1.44
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol (2012) 1.43
Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol (2005) 1.43
Stent fracture: an unusual cause of late restenosis after sirolimus-eluting stent placement. Catheter Cardiovasc Interv (2007) 1.42
High-frequency vibration for the recanalization of guidewire refractory chronic total coronary occlusions. Catheter Cardiovasc Interv (2008) 1.42
Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. Eur Heart J (2006) 1.42
Comparison of Bayesian model averaging and stepwise methods for model selection in logistic regression. Stat Med (2004) 1.40
The SIRIUS-DIRECT trial: a multi-center study of direct stenting using the sirolimus-eluting stent in patients with de novo native coronary artery lesions. Catheter Cardiovasc Interv (2007) 1.38
Prediction of sites of coronary atherosclerosis progression: In vivo profiling of endothelial shear stress, lumen, and outer vessel wall characteristics to predict vascular behavior. Curr Opin Cardiol (2003) 1.29
Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation (2003) 1.27
Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol (2003) 1.20
Reproducibility of coronary lumen, plaque, and vessel wall reconstruction and of endothelial shear stress measurements in vivo in humans. Catheter Cardiovasc Interv (2003) 1.20
Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation (2004) 1.20
Network news: powering clinical research. Sci Transl Med (2013) 1.19
Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol (2006) 1.18
Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. J Clin Oncol (2008) 1.16
Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. Am J Kidney Dis (2007) 1.14
The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J (2006) 1.13
Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J (2005) 1.12
Radiographically determined noninvasive adenocarcinoma of the lung: survival outcomes of Japan Clinical Oncology Group 0201. J Thorac Cardiovasc Surg (2013) 1.12
Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation (2002) 1.11
A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol (2009) 1.11
Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation (2005) 1.10
Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis. Heart (2013) 1.09
Long-term outcome of patients treated with repeat percutaneous coronary intervention after failure of gamma-brachytherapy for the treatment of in-stent restenosis. Circulation (2002) 1.08
Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol (2008) 1.06
A more balanced approach to drug-grapefruit juice interactions. BMJ (2013) 1.05
Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol (2004) 1.05
Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation (2005) 1.04
Effects of stent length and lesion length on coronary restenosis. Am J Cardiol (2004) 1.02
Regions of low endothelial shear stress are the sites where coronary plaque progresses and vascular remodelling occurs in humans: an in vivo serial study. Eur Heart J (2007) 1.02
Remodeling characteristics of minimally diseased coronary arteries are consistent along the length of the artery. Am J Cardiol (2005) 1.02
Risk assessment for percutaneous coronary intervention: our version of the weather report? J Am Coll Cardiol (2003) 1.01
The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study. Eur J Cardiovasc Prev Rehabil (2004) 1.00
Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service? Int J Cardiol (2005) 0.98
A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation. Am J Cardiol (2009) 0.97
Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Jpn J Clin Oncol (2008) 0.97
Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study. Health Policy (2004) 0.97
Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK). Eur Heart J (2004) 0.95
Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A). Gastric Cancer (2013) 0.94
A randomized controlled trial of the conventional technique versus the no-touch isolation technique for primary tumor resection in patients with colorectal cancer: Japan Clinical Oncology Group Study JCOG1006. Jpn J Clin Oncol (2013) 0.92
Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol (2006) 0.92
The changing structure of industry-sponsored clinical research: pioneering data sharing and transparency. Ann Intern Med (2013) 0.91
Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol (2014) 0.91
Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol (2014) 0.89
ACC/AHA 2007 methodology for the development of clinical data standards: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. J Am Coll Cardiol (2007) 0.89
Feasibility and cost of treatment with drug eluting stents of surgical candidates with multi-vessel coronary disease. Eur J Cardiothorac Surg (2004) 0.89
First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention (2005) 0.88
Embolic protection with filtering or occlusion balloons during saphenous vein graft stenting retrieves identical volumes and sizes of particulate debris. Circulation (2004) 0.87
Differences in the use of guideline-recommended therapies among 14 European countries in patients with acute coronary syndromes undergoing PCI. Eur J Prev Cardiol (2012) 0.87
Quantitative relationship between coronary vasodilator reserve assessed by 82Rb PET imaging and coronary artery stenosis severity. Eur J Nucl Med Mol Imaging (2008) 0.87
Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol (2006) 0.87
Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology? Ann Surg Oncol (2013) 0.86
Clinical and economic outcomes of percutaneous coronary interventions in the elderly: an analysis of medicare claims data. Circulation (2004) 0.86
Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device. Am J Cardiol (2005) 0.85